Thus, the lack of CXCL12–KRT19 coating of PDA cells is directly responsible for the enhanced intratumoral accumulation of activated CD8+ T cells and sensitivity to treatment with anti–PD-1 antibody. The gene discussed is CXCL12; the disease is Patent ductus arteriosus.